Deals Of The Week: Merck/Galapagos, Merck/Medarex, GSK/Stiefel ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies
Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.
Turning To Not-For-Profits, AstraZeneca Bolsters Early Stage R&D
With patent expirations of major drugs looming, pharmaceutical companies are looking to trim expenses, especially in R&D, where expansive budgets have not generated returns – at least in terms of marketable products.
Turning To Not-For-Profits, AstraZeneca Bolsters Early Stage R&D
With patent expirations of major drugs looming, pharmaceutical companies are looking to trim expenses, especially in R&D, where expansive budgets have not generated returns – at least in terms of marketable products.